Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EBMT 2023 | Indications for autologous stem cell transplantation in AML

Norbert-Claude Gorin • 23 Apr 2023
EBMT 2023
Acute Myeloid Leukemia Acute Promyelocytic Leukemia Leukemia Rare Diseases

Norbert-Claude Gorin, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, comments on the current indications for autologous stem cell transplantation (autoSCT) in acute myeloid leukemia (AML). This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Norbert-Claude Gorin

The impact of novel targeted & immune therapies in leukemia
1:33
The impact of novel targeted & immune therapies in leukemia
Norbert-Claude Gorin • 23 Apr 2023
The progress of the EBMT & key ongoing projects
1:08
The progress of the EBMT & key ongoing projects
Norbert-Claude Gorin • 23 Apr 2023
The evolution of stem cell transplantation
1:39
The evolution of stem cell transplantation
Norbert-Claude Gorin • 23 Apr 2023
Outcomes following FD & NFD related donor haplo transplantation for patients with acute leukemias
1:13
Outcomes following FD & NFD related donor haplo transplantation for patients with acute leukemias
Norbert-Claude Gorin • 23 Apr 2023

Related Videos

Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
2:08
Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
Norbert-Claude Gorin • 7 Dec 2025
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
1:10
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Norbert-Claude Gorin • 24 Nov 2025
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
1:16
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
Norbert-Claude Gorin • 24 Nov 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Norbert-Claude Gorin • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals